A phase I study of MM-10-001 in advanced non-small cell lung cancer.
M. Cristea,M. Koczywas,K. Reckamp,S. Lacey,A. Rotter,P. Frankel,S. Fouladi Rad,X. Liu,V. Tran,E. Reorizo,M. Kalos
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.7572
IF: 45.3
2011-05-20
Journal of Clinical Oncology
Abstract:7572 Background: MM-10-001 is a bioactive agent exported from Shiitake Mycelium in aqueous medium. The beta-glucan in MM-10-001 binds to a lectin site within the complement receptor 3 on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to iC3b-opsonized tumor cells. This phase I study was designed to assess the feasibility and toxicity of MM-10-001. Secondary endpoints included exploratory analysis of the effect of MM-10-001 on the innate immune compartment and the cytokine profile of the patients as well as antitumor efficacy.
METHODS
Patients with advanced NSCLC received orally escalating doses of MM-10-001 (5mg, 10 mg and 20 mg); a cycle consisted of 28 days. The blood samples for correlative studies were collected pre-study and weeks 1, 5, 9, 13. Serum cytokine levels were measured with 30-plex cytokine/ chemokine/growth factor multiplex panels (Invitrogen), and analyzed using a FLEXMAP-3D instrument (Luminex).
RESULTS
To date, 20 patients (7M/13F) have been treated (MM-10-001 5 - 20 mg). No grade 3+ treatment related adverse events were noted. Grade 2 adverse events reported are fatigue (3 pts), anorexia (1 pt), Alk Phos (1 pt), and joint pain (1 pt), each with an attribution of "possible". Median time to treatment failure was 3.5 months (range 1-13+ months). Correlative studies on 19 cytokines in addition to immunoglobulins (A, M, G), WBC, hemoglobin, PLT, ANC, CRP, and serum complements C3 and C4 were conducted on 18/20 subjects. Significant cytokine increases were noted in 3 patients concurrent with progression, resulting in a positive trend in several cytokines over time. Subset analysis, excluding those patients, suggested a possible decrease in IL-12 as a function of both time and dose (p=0.01, 0.02 respectively), along with a decrease in MIP1b as a function of dose (p=0.03). These results were not significant when adjusting for multiple comparisons. However, after accounting for multiple comparisons, low IL-2R was associated with improved survival (p<0.05, log-rank).
CONCLUSIONS
At the time of interim analysis, the MTD has not been reached and study will continue with escalating doses of MM-10-001. The preliminary data indicates potential immunostimulating activity of MM-10-001.